Update on ischemia-reperfusion injury in lung transplantation

Current Opinion in Organ Transplantation

Volumn 20, Issue 5, 2015, Pages 515-520

  Chen, Fengshi ^a   Date, Hiroshi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Ischemia reperfusion injury; Lung transplantation; Primary graft failure; Therapeutic gases

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARBON MONOXIDE; HYDROGEN; HYDROGEN SULFIDE; NITRIC OXIDE; PRESERVATION SOLUTION; SURFACTANT;

EX VIVO STUDY; FIBRINOLYTIC THERAPY; GRAFT PRESERVATION; HUMAN; LUNG PERFUSION; LUNG TRANSPLANTATION; LUNG VENTILATION; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; REPERFUSION INJURY; REVIEW; SURVIVAL RATE; ADVERSE EFFECTS; ANIMAL; DISEASE MODEL; ISCHEMIA; PERFUSION; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; ISCHEMIA; LUNG TRANSPLANTATION; PERFUSION; REPERFUSION INJURY; TREATMENT OUTCOME;

EID: 84957416144     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000234     Document Type: Review

References (43)

1. de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 2003;167:490-511.
2. Gielis JF, Boulet GA, Briede JJ, et al. Longitudinal quantification of radical bursts during pulmonary ischaemia and reperfusion. Eur J Cardiothorac Surg 2015. Jan 5. Pii: ezu518. (in press).
3. Lee JC, Christie JD, Keshavjee S. Primary graft dysfunction: definition, risk factors, short- and long-term outcomes. Semin Respir Crit Care Med 2010;31:161-171.
4. Wikes DS. Autoantibody formation in human and rat studies of chronic rejection and primary graft dysfunction. Semin Immunol 2012;24:131-135.
5. Yusen RD, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report-2014; focus theme: retransplantation. J Heart Lung Transplant 2014;33:1009-1024.
6. Nathan SD. The future of lung transplantation. Chest 2015;147:309-316.
7. Chen F, Nakamura T, Wada H. Development of new organ preservation solutions in Kyoto University. Yonsei Med J 2004;45:1107-1114.
8. Weyker PD, Webb CAJ, Kiamanesh D, Flynn BC. Lung ischemia reperfusion injury: a bench-to-beside review. Semin Cardiothorac Vasc Anesth 2012;17:28-43.
9. Chatterjee S, Nieman GF, Christie JD, Fisher AB. Shear stress-relatedmechanosignaling with lung ischemia: lessons from basic research can inform lung transplantation. Am J Physiol Lung Cell Mol Physiol 2014;307:L668-L680. The authors describe that understanding the key events in the mechanosignaling cascade has important lessons for the design of strategies or interventions that may reduce injury during storage of donor lungs with the goal to increase the availability of lungs suitable for donation.
10. Sayah DM, Mallavia B, Liu F, et al. Neutrophil extracellular traps are pathogenic in primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2015;191:455-463. These data are the first description of a pathogenic role for neutrophil extracellular traps in solid organ transplantation and suggest that neutrophil extracellular traps are a promising therapeutic target in primary graft dysfunction (PGD).
11. Fard N, Saffari A, Emami G, et al. Acute respiratory distress syndrome induction by pulmonary ischemia-reperfusion injury in large animal models. J Surg Res 2014;189:274-284.
12. Latchana N, Peck JR, Whitson B, Black SM. Preservation solutions for cardiac and pulmonary donor grafts: a review of the current literature. J Thorac Dis 2014;8:1143-1149.
13. Ikeda M, Bando T, Yamada T, et al. Clinical application of ET-K solution for lung transplantation. Surg Today 2015;45:439-443. Lungs preserved by ET-Kyoto solution had satisfactory postoperative lung function, despite the long preservation time, with excellent long-term survival.
14. Gohrbandt B, Simon AR, Warnecke G, et al. Lung preservation with Perfadex or Celsior in clinical transplantation: a retrospective single-center analysis of outcomes. Transplantation 2015. (in press).
15. Van De Wauwer C, Neyrinck AP, Rega FR, et al. Retrograde flush is more protective than heparin in the uncontrolled donation after circulatory death lung donor. J Surg Res 2014;187:316-323.
16. Mrazkova H, Lischke R, Hodyc D, Herget J. The protective effect of hypercapnia onischemia-reperfusioninjuryin lungs. Respir Physiol Neurobiol 2015;205:42-46.
17. Beer A, Reed RM, Bolukbas S, et al. Mechanical ventilation after lung transplantation: an international survey of practices and preferences. Ann Am Thorac Soc 2014;11:546-553. This is the first international survey ever done to describe the current practices of mechanical ventilation immediately after lung transplantation.
18. Diamond JM, Ahya VN. Mechanical ventilation after lung transplantation. It's time for a trial. Ann Am Thorac Soc 2014;11:598-599.
19. Munshi L, Keshavjee S, Cypel M. Donor management and lung preservation for lung transplantation. Lancet Respir Med 2013;1:318-328.
20. Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Eng J Med 2011;364:1431-1440.
21. Nakajima D, Chen F, Yamada T, et al. Reconditioning of lungs donated after circulatory death with normothermic ex vivo lung perfusion. J Heart Lung Transplant 2012;31:187-193.
22. Popov AF, Sabashnikov A, Patil NP, et al. Ex vivo lung perfusion - state of the art in lung donor pool expansion. Med Sci Monit Basic Res 2015;21:9-14.
23. Cypel M, Keshavjee S. Extending the donor pool: rehabilitation of poor organs. Thorac Surg Clin 2015;25:27-33. This review article describes that a novel strategy of donor lung management, called ex-vivo lung perfusion, can keep the organ in a physiologic protective condition and promises to increase lung utilization by reevaluating, treating, and repairing donor lungs before transplantation.
24. Sakamoto J, Chen F, Nakajima D, et al. The effect of beta-2 adrenoreceptor agonist inhalation on lungs donated after cardiac death in a canine lung transplantation model. J Heart Lung Transplant 2012;31:773-779.
25. Motoyama H, Chen F, Ohsumi A, et al. Protective effect of plasmin in marginal donor lungs in an ex vivo lung perfusion model. J Heart Lung Transplant 2013;32:505-510.
26. Motoyama H, Chen F, Ohsumi A, et al. Plasmin administration during ex vivo lung perfusion ameliorates lung ischemia-reperfusion injury. J Heart Lung Transplant 2014;33:1093-1099. The authors found that plasmin administration during ex-vivo lung perfusion protected the donor lungs after reperfusion and that several physiologic values in EVLP might be predictive markers of lung function after reperfusion.
27. Yamada T, Chen F, Sakamoto J, et al. Impact of the cardiac arrest mode on cardiac death donor lungs. J Surg Res 2015;195:596-603. This study aimed to assess the influence on lung injuries of the way in which cardiac arrest was induced (ventricular fibrillation and asphyxia) and to investigate the mechanisms leading to differences.
28. Herrmann G, Knudsen L, Madershahian N, et al. Effects of exogenous surfactant on the nonheart-beating donor lung graft in experimental lung transplantation - a stereological study. J Anat 2014;224:594-602.
29. Ohsumi A, Chen F, Sakamoto J, et al. Protective effect of prerecovery surfactant inhalation on lungs donated after cardiac death in a canine lung transplantation model. J Heart Lung Transplant 2012;31:1136-1142.
30. Okamoto T, Nakamura T, Zhang J, et al. Successful sub-zero nonfreezing preservation of rat lungs at -2°C utilizing a new supercooling technology. J Heart Lung Transplant 2008;27:1150-1157.
31. Bruinsma BG, Berendsen TA, Izamis ML, et al. Supercooling preservation and transplantation of the rat liver. Nat Protoc 2015;10:484-494.
32. Wu JX, Zhu HW, Chen X, et al. Inducible nitric oxide synthase inhibition reverses pulmonary arterial dysfunction in lung transplantation. Inflamm Res 2014;63:609-618.
33. Ryter SW, Choi AM. Carbon monoxide: present and future indications for a medical gas. Korean J Intern Med 2013;28:123-140.
34. Akhtar MZ, Sutherland AI, Huang H, et al. The role of hypoxia-inducible factors in organ donation and transplantation: the current perspective and future opportunities. Am J Transplant 2014;14:1481-1487.
35. Dark J. Hydrogen in lung conditioning - more than just inflation. Transplantation 2014;98:497-498.
36. Kawamura T, Wakabayashi N, Shigemura N, et al. Hydrogen gas reduces hyperoxic lung injury via the Nrf2 pathway in vivo. Am J Physiol Lung Cell Mol Physiol 2013;304:L646-L656.
37. Noda K, Shigemura N, Tanaka Y, et al. Hydrogen preconditioning during ex vivo lung perfusion improves the quality of lung grafts in rats. Transplantation 2014;98:499-506. Preconditioning lung grafts using inhaled hydrogen attenuated proinflammatory changes, promoted mitochondrial biogenesis in the lungs throughout the procedure, and resulted in better posttransplant graft function.
38. Haam S, Lee S, Paik HC, et al. The effects of hydrogen gas inhalation during ex vivo lung perfusion on donor lungs obtained after cardiac death. Eur J Cardiothorac Surg 2015. Mar. 6. pii: ezv057. (in press).
39. Liu H, Liang X, Wang D, et al. Combination therapy with nitric oxide and molecular hydrogen in a murine model of acute lung injury. Shock 2015;43:504-511. The authors, for the first time, demonstrated that combination therapy with nitric oxide and hydrogen provides enhanced therapeutic efficacy for acute lung injury.
40. Zhang P, Li F, Wiegman CH, et al. Inhibitory effect of hydrogen sulfide on ozone-induced airway inflammation, oxidative stress, and bronchial hyperresponsiveness. Am J Respir Cell Mol Biol 2015;52:129-137.
41. Souidi N, Stolk M, Seifert M. Ischemia-reperfusion injury: beneficial effects of mesenchymal stromal cells. Curr Opin Organ Transplant 2013;1:34-43.
42. Tian W, Liu Y, Zhang B, et al. Infusion of mesenchymal stem cells protects lung transplants from cold ischemia-reperfusion injury in mice. Lung 2015;193:85-95. The authors clearly demonstrated that mesenchymal stem cells provide significant protection against cold IRI in lung transplants, and thus mesenchymal stem cells may be a promising strategy to improve outcomes after lung transplantation.
43. Antunes MA, Laffey JG, Pelosi P, Rocco PR. Mesenchymal stem cell trials for pulmonary diseases. J Cell Biochem 2014;115:1023-1032.